2014-2016年解放军第264医院抗肿瘤药应用分析

Analysis on Application of Antineoplastic Drugs in the 264th Hospital of PLA During 2014-2015

目的:了解解放军第264医院(以下简称"我院")抗肿瘤药使用情况,为促进合理用药提供参考。方法:统计2014—2016年我院抗肿瘤药的年销售金额、不同种类抗肿瘤药的销售金额及其占比,以及每年销售金额排序居前10位的抗肿瘤药,以此分析抗肿瘤药临床应用情况。结果:2014—2016年我院抗肿瘤药销售金额分别为1 345 493.64、1 005 530.33、1 436 303.94元,2015年比2014年下降了25.27%,2016年比2015年增长了42.84%;抗代谢药的使用较多,其销售金额排序居第1位,其次为植物来源的抗肿瘤药、抗肿瘤激素类药物、抗肿瘤抗生素,传统抗肿瘤药如烷化剂等的销售金额较少且呈逐年递减的趋势;3年来,销售金额排序居前3位的药品包括卡培他滨片、替莫唑胺胶囊、注射用盐酸吉西他滨、替吉奥胶囊、多西他赛注射液。结论:我院抗肿瘤药的使用基本符合要求。临床用药时,应从药物经济学的角度,合理使用抗肿瘤药,减轻患者的经济负担,提高合理用药水平。

OBJECTIVE： To investigate the application status of antineoplastic drugs in the 264 th Hospital of PLA（ hereinafter referred to as＂our hospital＂）,so as to provide reference for the rational drug application. METHODS：Statistical analysis was conducted on the application data of antitumor drug＇s consumption amount,different kinds of antitumor drug consumption amount and proportion,the top 10 of antitumor drug consumption amount and proportion during 2014-2016,to analyze the clinical application. RESULTS： The consumption sum of antineoplastic drugs in our hospital were respectively 1 345 493. 64 yuan,1 005 530. 33 yuan and 1 436 303. 94 yuan during 2014-2016,which in 2015 was 25. 27% lower than in 2014,and in 2016 was 42. 84% higher than in 2015. The consumption sum of application of metabolism antineoplastic drugs took the lead,followed by plant sources of antineoplastic drugs,antitumor hormone drugs and antitumor antibiotics. Yet the application of traditional antineoplastic drugs as alkylating agent was relatively low and presented down trend. For three years,the top three drugs ranked by consumption sum were respectively temozolomide capsules,Capecitabine tablets,gemcitabine hydrochloride for injections,Gimeracil and oteracil porassium capsules and Docetaxel injections. CONCLUSIONS： The application of antineoplastic drugs in our hospital was basically rational. It is necessary to enhance the rational application of antineoplastic drugs so as to reduce the economic burden of patients and improve the level of rational drug application from the perspective of pharmacoeconomics during the course of clinic application.